Risk assessment of disease recurrence in early breast cancer : A serum metabolomic study focused on elderly patients
Copyright © 2022. Published by Elsevier Inc..
BACKGROUND: We previously showed that metabolomics predicts relapse in early breast cancer (eBC) patients, unselected by age. This study aims to identify a "metabolic signature" that differentiates eBC from advanced breast cancer (aBC) patients, and to investigate its potential prognostic role in an elderly population.
METHODS: Serum samples from elderly breast cancer (BC) patients enrolled in 3 onco-geriatric trials, were retrospectively analyzed via proton nuclear magnetic resonance (1H NMR) spectroscopy. Three nuclear magnetic resonance (NMR) spectra were acquired for each serum sample: NOESY1D, CPMG, Diffusion-edited. Random Forest (RF) models to predict BC relapse were built on NMR spectra, and resulting RF risk scores were evaluated by Kaplan-Meier curves.
RESULTS: Serum samples from 140 eBC patients and 27 aBC were retrieved. In the eBC cohort, median age was 76 years; 77% of patients had luminal, 10% HER2-positive and 13% triple negative (TN) BC. Forty-two percent of patients had tumors >2 cm, 43% had positive axillary nodes. Using NOESY1D spectra, the RF classifier discriminated free-from-recurrence eBC from aBC with sensitivity, specificity and accuracy of 81%, 67% and 70% respectively. We tested the NOESY1D spectra of each eBC patient on the RF models already calculated. We found that patients classified as "high risk" had higher risk of disease recurrence (hazard ratio (HR) 3.42, 95% confidence interval (CI) 1.58-7.37) than patients at low-risk.
CONCLUSIONS: This analysis suggests that a "metabolic signature", identified employing NMR fingerprinting, is able to predict the risk of disease recurrence in elderly patients with eBC independently from standard clinicopathological features.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Translational oncology - 27(2023) vom: 15. Jan., Seite 101585 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Risi, Emanuela [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Breast cancer |
|---|
| Anmerkungen: |
Date Revised 22.12.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.tranon.2022.101585 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349167133 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349167133 | ||
| 003 | DE-627 | ||
| 005 | 20231226041957.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tranon.2022.101585 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1163.xml |
| 035 | |a (DE-627)NLM349167133 | ||
| 035 | |a (NLM)36403505 | ||
| 035 | |a (PII)S1936-5233(22)00244-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Risi, Emanuela |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk assessment of disease recurrence in early breast cancer |b A serum metabolomic study focused on elderly patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2022. Published by Elsevier Inc. | ||
| 520 | |a BACKGROUND: We previously showed that metabolomics predicts relapse in early breast cancer (eBC) patients, unselected by age. This study aims to identify a "metabolic signature" that differentiates eBC from advanced breast cancer (aBC) patients, and to investigate its potential prognostic role in an elderly population | ||
| 520 | |a METHODS: Serum samples from elderly breast cancer (BC) patients enrolled in 3 onco-geriatric trials, were retrospectively analyzed via proton nuclear magnetic resonance (1H NMR) spectroscopy. Three nuclear magnetic resonance (NMR) spectra were acquired for each serum sample: NOESY1D, CPMG, Diffusion-edited. Random Forest (RF) models to predict BC relapse were built on NMR spectra, and resulting RF risk scores were evaluated by Kaplan-Meier curves | ||
| 520 | |a RESULTS: Serum samples from 140 eBC patients and 27 aBC were retrieved. In the eBC cohort, median age was 76 years; 77% of patients had luminal, 10% HER2-positive and 13% triple negative (TN) BC. Forty-two percent of patients had tumors >2 cm, 43% had positive axillary nodes. Using NOESY1D spectra, the RF classifier discriminated free-from-recurrence eBC from aBC with sensitivity, specificity and accuracy of 81%, 67% and 70% respectively. We tested the NOESY1D spectra of each eBC patient on the RF models already calculated. We found that patients classified as "high risk" had higher risk of disease recurrence (hazard ratio (HR) 3.42, 95% confidence interval (CI) 1.58-7.37) than patients at low-risk | ||
| 520 | |a CONCLUSIONS: This analysis suggests that a "metabolic signature", identified employing NMR fingerprinting, is able to predict the risk of disease recurrence in elderly patients with eBC independently from standard clinicopathological features | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a Elderly | |
| 650 | 4 | |a Metabolomics | |
| 650 | 4 | |a NMR spectroscopy | |
| 650 | 4 | |a Prognosis | |
| 700 | 1 | |a Lisanti, Camilla |e verfasserin |4 aut | |
| 700 | 1 | |a Vignoli, Alessia |e verfasserin |4 aut | |
| 700 | 1 | |a Biagioni, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Paderi, Agnese |e verfasserin |4 aut | |
| 700 | 1 | |a Cappadona, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Monte, Francesca Del |e verfasserin |4 aut | |
| 700 | 1 | |a Moretti, Erica |e verfasserin |4 aut | |
| 700 | 1 | |a Sanna, Giuseppina |e verfasserin |4 aut | |
| 700 | 1 | |a Livraghi, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Malorni, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Benelli, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Puglisi, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Luchinat, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Tenori, Leonardo |e verfasserin |4 aut | |
| 700 | 1 | |a Biganzoli, Laura |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Translational oncology |d 2008 |g 27(2023) vom: 15. Jan., Seite 101585 |w (DE-627)NLM180720333 |x 1936-5233 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2023 |g day:15 |g month:01 |g pages:101585 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.tranon.2022.101585 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2023 |b 15 |c 01 |h 101585 | ||